Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0029
-0.0003 (-9.38%)
Apr 29, 2026, 2:56 PM CET
-97.50%
Market Cap 1.94M
Revenue (ttm) n/a
Net Income (ttm) -32.44M
Shares Out 605.93M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,692,388
Average Volume 13,666,350
Open 0.0032
Previous Close 0.0032
Day's Range 0.0029 - 0.0032
52-Week Range 0.0028 - 0.1935
Beta 0.38
RSI 34.08
Earnings Date May 22, 2026

About STO:LPGO

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leader... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol LPGO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.